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Background: The cloning of gene sequences forms the basis for many molecular biological studies. One important
step in the cloning process is the isolation of bacterial transformants carrying vector DNA. This involves a vector-
encoded selectable marker gene, which in most cases, confers resistance to an antibiotic. However, there are a
number of circumstances in which a different selectable marker is required or may be preferable. Such situations
can include restrictions to host strain choice, two phase cloning experiments and mutagenesis experiments, issues
that result in additional unnecessary cloning steps, in which the DNA needs to be subcloned into a vector with a
suitable selectable marker.
Results: We have used restriction enzyme mediated gene disruption to modify the selectable marker gene of a
given vector by cloning a different selectable marker gene into the original marker present in that vector. Cloning a
new selectable marker into a pre-existing marker was found to change the selection phenotype conferred by that
vector, which we were able to demonstrate using multiple commonly used vectors and multiple resistance markers.
This methodology was also successfully applied not only to cloning vectors, but also to expression vectors while
keeping the expression characteristics of the vector unaltered.
Conclusions: Changing the selectable marker of a given vector has a number of advantages and applications. This
rapid and efficient method could be used for co-expression of recombinant proteins, optimisation of two phase
cloning procedures, as well as multiple genetic manipulations within the same host strain without the need to
remove a pre-existing selectable marker in a previously genetically modified strain.
Keywords: Molecular cloning, Gene disruption, Selection of transformants, Antibiotic resistanceBackground
Molecular cloning is a process involving the incorpor-
ation of a copy of a gene or gene fragment into a plas-
mid vector [1]. This process allows the characterisation
of genes and their associated gene products from any
organism. Hence, the ability to clone genes for their
characterisation completely revolutionised molecular
biology and our understanding of cell biology.
Most cloning vectors are taken up, stably maintained
and efficiently replicated in Escherichia coli. As a result,
E. coli is commonly used as a tool for cloning. Given the
low efficiency of vector transformation, one important* Correspondence: C.Barth@latrobe.edu.au
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reproduction in any medium, provided the orstep in the cloning process is the selection of cellular
clones carrying vector DNA, termed transformants [2].
Selection will only allow cells carrying vector DNA to
grow, while untransformed cells are inhibited or killed
due to the presence of a selective agent [3]. For molecu-
lar cloning in E. coli, selection of transformants carrying
vector DNA often involves using antibiotics which are
supplemented into the growth medium. This is because
the vector contains a gene encoding resistance to a
particular antibiotic, termed a selectable marker gene
[2,3]. Due to this resistance being vector-encoded, the
resistance phenotype is only conferred to transformants
carrying the vector. Additionally, the selective pressure
placed upon transformants by using selective agents,
forces the E. coli host to maintain and replicate the
vector. Given that maintenance of a vector, whichLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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transformants at a growth disadvantage, a lack of selec-
tion can promote vector loss [4].
For the selection of vectors in E. coli, there is an array of
selective agents and associated selectable marker genes
encoded in these vectors. While such agents include ionic
heavy metals such as mercury, it is antibiotics that are
most commonly used for selecting E. coli transformants
[4]. One of the most common antibiotics utilised is ampi-
cillin. Vector-encoded ampicillin resistance genes usually
encode β-lactamases, which enzymatically inactivate
ampicillin [3,5,6]. While ampicillin selection provides a
number of advantages, there are often circumstances in
which selection with a different antibiotic is desired. For
example, β-lactamases are produced at substantial levels,
and are secreted into the medium. Prolonged incubation
of these cells results in the inactivation of all ampicillin in
the medium [3,4]. Thus, after a significant period of time
into incubation, cells will continue growing in the absence
of selective pressure. In transformation experiments, this
will lead to the formation of ampicillin sensitive satellite
colonies.
Additionally, maintaining two different vectors within
one host cell often requires differing selectable markers
for each vector. If both vectors confer resistance to the
same antibiotic, the selective pressure will often not be
sufficient for the host to maintain both replicons. More-
over, many host strains have been genetically modified
and as a result, carry resistance to specific antibiotics.
This innate resistance means that vectors conferring re-
sistance to the same antibiotic are not suitable for this
strain. This presents an issue when such restrictions
mean the researcher is forced to choose either another
strain or another vector, which may be less suitable for
the experiment of interest. Additionally, other genetic
manipulation methods, such as mutagenesis or conjuga-
tion experiments, also require the use of selectable
markers for which limited choices are also available.
Furthermore, difficulties can also be encountered when
a cloned DNA sequence of interest is in a vector that
does not carry a suitable selectable marker and thus,
needs to be subcloned into a different vector. Thus, the
ability to rapidly change the selectable marker capabil-
ities of an existing vector or construct of interest is a
highly desirable feature in many aspects of genetic
research, such as improving molecular cloning and
transformant selection methods.
Here, we report a cloning procedure that involves al-
tering the selectable marker gene of a vector of interest
by introducing another. This is performed using restric-
tion enzyme mediated gene inactivation in which
the initial vector encoded selectable marker gene is
inactivated by cloning another selectable marker gene
into the original open reading frame (ORF). Using thisprocess to expand selectable marker choice has a
number of potential applications and provides multiple
benefits for many procedures including cloning, muta-
genesis, host strain choice and vector choice.
Methods
PCR amplification of tetracycline and kanamycin
selectable marker genes
The tetA gene cassette was amplified using pLAFR1 vec-
tor as a template with forward primer 5′-CCATGGC
TGCAGAGTACTGTTTCCACGATCAGCGATCGGCT
CG-3′ and reverse primer 5′-CCATGGCTGCAGAGTA
CTGGCACGGATCACTGTATTCGGCTGC-3′. These
primers had restriction sites for NcoI, PstI and ScaI incor-
porated for cloning purposes. The kanR gene cassette was
amplified using the pZErO-2 vector as template with for-
ward primer 5′-AGTACTCAAACTGGAACAACACTC
AACCCTATCG-3′ and reverse primer 5′-AGTACTCAC
CTAGATCCTTTTCACGTAGAAAGCC-3′. These
primers had restriction sites for ScaI incorporated for
cloning purposes. PCR reactions were performed under
the following cycling conditions; 94°C for 5 min and
then 40 cycles of 94°C for 1 min, 60°C for 30 seconds,
72°C for 1 min followed by a final extension at 72°C for
11 min.
Cloning of tetracycline and kanamycin selectable marker
genes
The tetA and kanR gene cassettes have been amplified
by PCR using gene specific primers as described above.
The amplification products were cloned into the phase I
vector pCRW2.1-TOPOW (Invitrogen) according to the
manufacturer’s instructions. The phase I constructs and
the phase II vectors were then digested with the relevant
restriction enzyme in order to clone into the ORF of the
phase II vector’s selectable marker gene. The gel puri-
fied insert and vector were then used in a ligation reac-
tion using T4 DNA ligase (Promega). Cohesive end
ligations were performed at 16°C/23°C cycling condi-
tions for 12 hours, while blunt end ligations were
performed at 15°C for 12 hours. Aliquots of the ligation
reaction were then electroporated into E. coli DH5α or
TOP10 cells at a capacitance of 25 μF at 2.5 kV with a
resistance of 200Ω. The transformation was plated onto
Luria Bertani (LB) agar supplemented with the anti-
biotic to which the insert confers resistance (tetracycline
or kanamycin, 5 μg/ml and 25 μg/ml, respectively).
Viable transformant counts
In order to determine the number of viable cells and
their ability to grow in the presence of different antibi-
otics, overnight cultures were serially diluted to 10-7.
The E. coli transformation mixtures of interest were
then plated out onto LB agar containing either no
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or tetracycline (5 μg/ml). Viable transformant counts
were calculated based on the number of colonies
obtained on duplicate plates of the same dilution within
a statistically valid range.
Southern blot hybridisation
Vector DNA was linearised and run on a 1% (w/v) agarose
gel. The gel was washed in depurination (0.25 M HCl),
neutralisation (0.5 M Tris–HCl, pH 7.0) and denaturation
(1.5 M NaCl, 0.4 M NaOH) solutions, and the DNA was
transferred to a nylon membrane (Hybond). After the
membrane was baked at 80°C for 2 hours, the membrane
was prehybridised in hybridisation buffer (25% 20 × SSC
[3 M NaCl, 0.3 M Tri-sodium citrate], 50% formamide,
0.1% N-lauroyl-sarcosine, 0.02% SDS, 2% blocking solu-
tion) at 42°C overnight. The pBR328 vector DIG labelled
control probe provided with the DIG labelling and detec-
tion kit (Roche) was used as a probe to detect vector DNA
and was added to the hybridisation buffer at 25 ng/ml.
After incubating overnight, DIG detection was performed
using colourimetric detection according to the manufac-
turer’s instructions.
Results
Restriction enzyme mediated gene disruption for
changing selectable markers
In order to establish a simple method for modifying the
selectable marker gene in commonly used E. coli vectors,
four different vectors and two resistance cassettes confer-
ring resistance to kanamycin and tetracycline were used
(Table 1). Two of the vectors, pUC19 [7-9] and pZErO-2
(Invitrogen), are commonly used for phase I cloning. The
vector pBlueScript SK(+) (Stratagene), is a phagemid,
which is widely used for in vitro transcription of cloned
DNA [10]. The final source vector used, pET23a
(Novagen) is an E. coli expression vector which was
employed to further demonstrate the versatility and
potential applications of this selection modification
method. The cloning strategies are outlined in Table 1
and in Figures 1 and 2.
Once a suitable restriction site within the existing






pUC19 (New England Biolabs) ampR ScaI
pUC19 (New England Biolabs) ampR ScaI
pZErO-2 (Invitrogen) kanR NcoI
pBlueScript SK + (Stratagene) ampR ScaI
pET23a (Novagen) ampR PstI
ampR : Ampicillin resistance, kanR : Kanamycin resistance, tetR : Tetracycline resistanprimers were designed to PCR amplify the tetA and
kanR gene cassettes (conferring resistance to tetracyc-
line and kanamycin, respectively) and their associated
regulatory elements, using other vectors containing
these genes as templates. The tetracycline resistance
locus in pLAFR1 consists of two genes, tetA and tetR
[11-13]. The tetA gene encodes an efflux pump respon-
sible for the resistance phenotype, while tetR encodes a
regulatory repressor protein [13-15]. As negative regula-
tion was not required, only the tetA gene was amplified.
The kanR gene, amplified from pZErO-2, encodes a
aminophosphotransferase, APH(3′)-II isolated from
transposon tn5, which confers resistance to kanamycin
via enzymatic inactivation [2,16].
Creation and isolation of transformants carrying vectors
with the new selectable marker gene
Following amplification and cloning of the tetA and
kanR cassettes into pCRW2.1-TOPOW (Invitrogen) phase
I vector (data not shown), the cloned resistance cas-
settes and target vectors of interest were digested with
the suitable restriction enzyme (Table 1). After ligation
and transformation of E. coli, cultures were plated onto
LB agar supplemented with the antibiotic for which the
insert encodes resistance. This allowed for selection of
the transformants carrying the construct of interest.
Transformants carrying empty, recircularised vectors
were therefore selected against on this medium. Both
the tetA and kanR resistance cassettes were successfully
cloned into the ampR gene of pUC19 (Figures 1 and 2).
The tetA resistance cassette was also cloned into the
kanR and ampR genes of pZErO-2 and pET23a, respect-
ively (Figure 2). Lastly, the kanR resistance cassette was
also cloned into the ampR gene of pBlueScript (Figure 1).
Cloning a new resistance cassette into the original
selectable marker gene of any vector abolishes the
original resistance phenotype and subsequently confers
resistance to a different antibiotic
In order to determine if restriction enzyme mediated
gene disruption inactivated the original vector resist-
ance ORF, viable transformant counts were performed
for E. coli transformants carrying either the originalble marker gene disruption




kanR pBlueScript SK+: kanR
tetR pET23a:tetA
ce.
Figure 1 Strategies employed for cloning a kanamycin resistance cassette (kanR) via selectable marker restriction enzyme mediated
gene disruption. The cassette was cloned into the unique ScaI site present in the ampR gene of pUC19 and pBlueScript SK+. Relevant restriction
sites and features of each vector are indicated.
Figure 2 Strategies employed for cloning a tetracycline resistance cassette (tetA) via selectable marker restriction enzyme mediated
gene disruption. The cassette was cloned into the resistance genes of pUC19, pZErO-2 and pET23a using unique restriction sites located in the
selectable marker of each vector. Relevant restriction sites and features of each vector are indicated.
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Table 2 Viable transformant counts of E. coli
transformants carrying vectors with an undisrupted or
disrupted ampicillin selectable marker
Viable transformant count (cfu/ml) on medium
Transformant LB LB + Amp LB + Tet
pUC19 2.22 × 109 2.25 × 109 0
pUC19:tetA 4.2 × 109 0 2.85 × 109
pET23a 2.85 × 109 2.39 × 109 0
pET23a:tetA 2.03 × 109 0 2.11 × 109
Disruptants were created by cloning a tetracycline selectable marker gene into
a unique restriction site in the vector encoded ampicillin resistance gene.
Transformants were plated onto LB medium supplemented with either
ampicillin or tetracycline. cfu; colony forming unit.
Table 4 Viable transformant counts of E. coli
transformants carrying vectors with an undisrupted or
disrupted ampicillin selectable marker
Viable transformant count (cfu/ml) on medium
Transformant LB LB + Amp LB + Kan
pUC19 2.22 × 109 2.25 × 109 0
pUC19:kanR 6.7 × 108 0 7.3 × 108
pBlueScript 2.87 × 109 2.81 × 109 0
pBlueScript:kanR 2.05 × 109 0 1.78 × 109
Disruptants were created by cloning a kanamycin selectable marker gene into
a unique restriction site in the vector encoded ampicillin resistance gene.
Transformants were plated onto LB medium supplemented with either
ampicillin or kanamycin. cfu; colony forming unit.
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marker. For all five constructs, the transformants only
grew in the presence of the antibiotic for which the
cloned gene encodes resistance to (Tables 2, 3, 4). This
indicates that insertion of a new selectable marker gene
into the original resistance ORF of a vector confers
resistance to a new antibiotic, and that the vector no
longer provides resistance to the original antibiotic as a
result of gene disruption. This phenotype was observed
for all transformants carrying any of the five constructs,
while transformants carrying the empty, original vector
displayed the opposite resistance profile. It is also
important to note that the practical value of the con-
structs as cloning vectors remained unaffected, since
this method only involved disruption of the selectable
marker gene, leaving the multiple cloning sites and
other regulatory features of these vectors intact. This
was demonstrated by the successful cloning of a foreign
DNA sequence (590 bp in size) into the SacI and
HindIII restriction sites in the multiple cloning site of
the vector pET23a:tetA (Figure 3).Determining relative vector copy number in co-
transformed cells for expression vectors
In order to investigate the suitability of pET23a:tetA
for expression experiments in E. coli, the stability and
relative copy number of pET23a and pET23a:tetA wereTable 3 Viable transformant counts of E. coli
transformants carrying vectors with an undisrupted or
disrupted kanamycin selectable marker
Viable transformant count (cfu/ml) on medium
Transformant LB LB + Kan LB + Tet
pZErO 2.05 × 109 1.35 × 109 0
pZErO:tetA 1.06 × 107 0 1.07 × 107
Disruptants were created by cloning a tetracycline selectable marker gene into
a unique restriction site in the vector encoded kanamycin resistance gene.
Transformants were plated onto LB medium supplemented with either
kanamycin or tetracycline. cfu; colony forming unit.determined in transformants individually, as well as in
cells co-transformed with both vectors. Southern blot
hybridisation analysis demonstrated that vector copy
number from cells carrying either pET23a or pET23a:
tetA were similar (Figure 4). When both vectors were
introduced into the same host, they were both
maintained under selective pressure despite the incom-
patibility of their replication origins, and the cellsFigure 3 Restriction digest analysis of the vector pET23a:tetA
carrying a foreign DNA segment. Cloning of a 590 bp foreign
DNA was performed using SacI and HindIII restriction sites located
within the multiple cloning site of pET23a:tetA. Lane 1: 1 kb gene
ruler DNA ladder (sizes as indicated in kb); lane 2: pET23a:tetA vector
undigested; lane 3: pET23a:tetA, digested with SacI and HindIII
(5.01 kb); lane 4: pET23a:tetA, digested with EcoRV, a restriction site
located within the tetA gene (5.02 kb); lane 5: pET23a:tetA vector
carrying a 590 bp cloned DNA segment, undigested; lane 6: pET23a:
tetA vector carrying a 590 bp cloned DNA segment, digested with
SacI and HindIII (0.59, 5.01 kb); lane 7: pET23a:tetA vector containing
cloned DNA, digested with EcoRV, a restriction site located within
both the tetA gene and the cloned DNA (3.30, 2.30 kb).
Figure 4 Analysis of relative vector copy number of pET23a
and pET23a:tetA in E. coli co-transformed cells. The blot displays
signals for EcoRI linearised vectors from individual transformants
carrying the original pET23a vector (lane 1), the pET23a:tetA (lane 2),
or vector DNA from co-transformants carrying both pET23a and
pET23a:tetA vectors (lane 3).
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tetracycline (data not shown). However, pET23a:tetA
displayed a reduced copy number compared to pET23a,
which only seemed to occur in the presence of pET23a.
Discussion
Restriction enzyme mediated gene disruption inactivates
the function of the original selectable marker and
provides a novel selection system
Selection of bacterial transformants is an important step
in both the cloning of DNA and for the maintenance of
vector DNA in bacterial cells. The type of selectable
marker present in a particular vector is often an import-
ant consideration in multiple aspects of research. On
many occasions, there is a lack of choice when choosing
a vector and its selection capabilities. Here, we have
demonstrated a procedure to easily change the selectable
marker gene in desired cloning vectors by restriction
enzyme mediated gene disruption.
Restriction enzyme mediated gene disruption is a well
established method in molecular cloning and is primar-
ily used to distinguish between E. coli transformants
carrying an empty vector and those carrying a vector
with a cloned insert. The best known example of this is
blue-white screening, which involves cloning the DNA
of interest into the LacZα gene encoding the α subunit
of the β-galactosidase enzyme [17]. TransformantsTable 5 Commonly used vectors and unique restriction sites s
mediated gene disruption
Vector Selectable marker Source
pUC18, pUC19 ampR New Englan
pBlueScript ampR Stratagene
pZErO kanR Invitrogen
pBR322 ampR tetR New Englan
pACYC177 ampR kanR New Englan
pACYC184 camR tetR New Englan
ampR : ampicillin resistance, kanR : kanamycin resistance, tetR : tetracycline resistanccarrying the empty vector (and an intact LacZα gene)
produce blue colonies in the presence of X-gal, the
β-galactosidase substrate. On the other hand, in
transformants carrying vectors with cloned inserts, the
LacZα gene has been disrupted and the colonies remain
white [18,19].
Restriction enzyme mediated gene disruption was also
traditionally used in the inactivation of selectable marker
genes for identifying transformants carrying vectors with
the cloned insert. The pACYC vectors contain multiple
antibiotic resistance genes within the one vector and one
of the resistance genes contains a cloning site. Hence,
cloning DNA into these vectors inactivated one of the
antibiotic resistance genes and therefore transformants
carrying the cloned DNA would be sensitive to this anti-
biotic, while remaining resistant to the second antibiotic
conferred by the intact resistance gene [17,20].
Here, we have utilised the same principle, but instead
of using it to screen for transformants carrying vectors
with cloned inserts, we have used it to change the
selection capabilities of vectors. Insertion of either the
tetA or kanR genes into the original selectable marker
of multiple vectors was found to abolish the original
resistance phenotype conferred by the original ORF
and provides resistance to another antibiotic that was
encoded by the cloned DNA (Tables 2, 3, 4).
Significance of selectable marker restriction enzyme
mediated gene disruption
Restriction enzyme mediated gene disruption to change
the antibiotic resistance gene in a vector provides mul-
tiple advantages, especially due to the versatility and
simplicity of the process. We have shown that this
method can be used to easily change the selection pro-
file of commonly used E. coli vectors, including both
cloning and expression vectors, thereby increasing the
availability of suitable vectors. The method is simple, as
any restriction site of interest can be chosen as long as
it is unique and located within the original antibiotic re-
sistance ORF, and we have provided a list of commonly
used vectors and suitable restriction sites for selectable
marker gene disruption in Table 5.uitable for selectable marker restriction enzyme
Unique restriction sites in selectable marker
d Biolabs XmnI, ScaI
ScaI
NcoI
d Biolabs ScaI, PvuI, PstI EcoRV, BamHI, SphI, SalI
d Biolabs ScaI, PstI, BglI ClaI, HindIII
d Biolabs EcoRI, NcoI EcoRV, BamHI, SphI, SalI
e, camR : chloramphenicol resistance.
Manna et al. BMC Research Notes 2013, 6:85 Page 7 of 9
http://www.biomedcentral.com/1756-0500/6/85The method is also simple, as it requires only one
additional cloning step to create the desired vector, and
the screening process for transformants of interest is
rapid and efficient. This is because construct carrying
transformants can be isolated on media supplemented
with the antibiotic for which resistance is encoded for
by the cloned gene. For example, pUC19 transformants
can grow on ampicillin but cannot grow on tetracycline.
On the other hand, pUC19 transformants carrying the
tetA cassette display the opposite growth characteristics
(Table 2). Therefore, all transformants obtained on
tetracycline plates were highly likely to contain vectors
with the tetA cassette integrated into the ampR gene.
Thus this method can be applied to vectors to be used
in downstream cloning applications. Additionally, it can
also be used to modify the selectable marker of an
existing construct containing cloned DNA, rather than
having to repeat the cloning of the DNA of interest into
a different vector with suitable selection capabilities,
which can be tedious and time consuming.
Although ampicillin is widely used in cloning as a select-
ive agent, there are multiple disadvantages of working
with ampicillin. Ampicillin is inactivated by β-lactamases,
enzymes encoded by ampicillin resistance genes [3,5,6].
Given that they are expressed at high levels and are se-
creted by cells, the medium is quickly exhausted of ampi-
cillin during incubation [3,4]. This results in continual
growth of bacterial cultures in the absence of selection,
which can result in loss of vector DNA and ampicillin
sensitive satellite colonies arising in transformations. Add-
itionally, high concentrations of ampicillin (~100 μg/ml)
are often required and ampicillin solutions cannot be
stored for extended periods of time. In contrast, tetracyc-
line resistance conferred by tetA is based on an efflux
pump mechanism [13-15] and as a result, tetracycline is
never inactivated but present during the entire incubation,
maintaining selective pressure. Also, in comparison to
ampicillin, tetracycline usually requires much lower con-
centrations (~5 μg/ml). As a result, tetracycline may be a
more attractive antibiotic for use in molecular cloning
over ampicillin. Therefore, the pUC19:tetA construct
created via restriction enzyme mediated gene disruption
provides a beneficial vector for use in molecular cloning
over its parental vector (pUC19).
Applications of selectable marker restriction enzyme
mediated gene disruption in molecular cloning and
studying cell biology
The versatility of selectable marker gene disruption via
cloning also means that there are a number of applica-
tions to this method for studying cell biology. Firstly,
changing the selection capabilities of a vector can sig-
nificantly improve and facilitate the cloning of a DNA
fragment of interest. If the selectable marker gene ofeither the phase I or phase II vector is changed via
restriction enzyme mediated gene disruption, the two
vectors now confer different resistance phenotypes. As a
result, subcloning from the phase I to the phase II vec-
tor is possible without the need to purify the insert from
the phase I backbone. Although the ligation reaction
will now also include the phase I vector as well as the
insert and phase II vector, selection of the transformants
can be based on the resistance conferred by the phase II
vector. Thus, transformants containing any recombin-
ant form of the phase I vector will be selected against
and will not grow on the medium. This improves clon-
ing efficiency and allows evasion of purification proce-
dures, such as gel extraction, which can degrade the
ends of the insert as well as the unavoidable contamin-
ation of agarose which, can contain DNA ligase
inhibiting components [21,22]. Other purification
methods such as phenol chloroform extraction can leave
traces of phenol, which can also interfere with subse-
quent ligation reactions. Additionally, the purification
methods do not always completely remove the phase I
vector backbone, and phase I vector contamination in
phase II ligations and transformations will make screen-
ing for recombinants more laborious, if the phase I
vector is not selected against. For example, if a DNA
fragment of interest was subcloned from pUC19 (ampR)
to pET23a (ampR), pUC19 contamination will lower the
chance of obtaining the desired construct. However, this
can be avoided if pET23a:tetA (Figure 2) was used
instead, as selection would be performed based on tetra-
cycline resistance instead of ampicillin resistance.
While vector-based antibiotic resistance is most com-
monly used to isolate and maintain vector constructs in
E. coli, it also forms the basis for the generation of
bacterial strains via insertional mutagenesis. However,
many E. coli strains used for mutagenesis studies already
have resistance to particular antibiotics [18], and other
E. coli strains, as well as many other bacteria, have
innate resistance to specific antibiotics [3,18]. In these
circumstances, the choice of selectable markers and
suitable vectors is greatly restricted. To overcome this,
restriction enzyme mediated gene disruption can be
used to change the selection phenotype conferred by
the particular vector being used, by choosing a select-
able marker to which the strain of interest is not already
resistant. Similarly, this method also allows for suc-
cessive gene manipulations in the same strain and
facilitates the isolation of double mutants making
the need for methods such as the cre-lox system for
reusing the same selectable marker unnecessary.
While the cre-lox system can provide benefits for the
removal and reuse of selectable markers in particular
strains [23], using restriction enzyme mediated gene
disruption offers a simpler and less time consuming
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same strain.
Most vectors used for the heterologous expression of
recombinant proteins in E. coli possess ampicillin resist-
ance genes [24]. In fact, there are very few E. coli
expression vectors that have a resistance gene other
than ampicillin. This can present an issue given the
disadvantages of working with ampicillin discussed
above, but can also limit the choice of vectors for co-
expression studies. Using selectable marker restriction
enzyme mediated gene disruption, we modified the
selectable marker of pET23a (Novagen), a commonly
used expression vector. This involved inactivation of the
ampR gene, via the successful introduction of the tetA
gene cassette, which was confirmed at the phenotypic
level (Table 2). Similar to the original vector, the
pET23a:tetA construct can now be used for cloning and
subsequent protein expression, and we also demon-
strated that both vectors are maintained and transmit-
ted to daughter cells when co-transformed in the same
host, despite the incompatibility of their replication
origins. Using this method to change the selectable
marker gene of an expression vector therefore allows
the co-expression of two recombinant proteins within
the one host cell as both vectors can be maintained
under selective pressure, regardless if the replication or-
igins of the two vectors are incompatible. Co-expression
of recombinant proteins in the same host is important
for the study of protein-protein interactions or the co-
expression of molecular chaperones to improve the
folding and solubility of a particular recombinant
protein [25,26]. Using restriction enzyme mediated gene
disruption to change the selectable marker of protein
expression vectors allows such applications to be improved.
Conclusions
We have described a method in which the basic principles
of cloning have been utilised to change the antibiotic
resistance phenotype conferred by an E. coli vector by
cloning a different resistance gene into the original ORF.
This simple and rapid method has a number of advantages
including high versatility and options for researchers. It
also has applications in cloning, mutagenesis studies and
heterologous protein expression. Therefore, as a method,
selectable marker restriction enzyme mediated gene
disruption can provide a significant contribution to study-
ing molecular biology in bacteria as well as in other
organisms.
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